Vanda Pharmaceuticals (VNDA) said Friday morning that the US Food and Drug Administration has designated the company's VGT-1849A product candidate as an orphan drug to treat polycythemia vera, a rare form of hematologic malignancy affecting about one in every 2,000 people in the country.
The FDA uses orphan drug designation to incentivize the development of prospective treatments for conditions affecting relatively few people. Therapies receiving the designation are eligible for selected tax credits and exemption from certain fees and up to seven years of market exclusivity following regulatory approval.
Vanda shares recently were up 1.5% during Friday morning trade.
Price: 4.70, Change: +0.07, Percent Change: +1.51
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.